Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.

Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share.  The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.

Member Ari Feder was quoted by The Globe and Mail in an article about how the new tariffs imposed by the Trump administration are affecting Apple.

Mintz has appointed Members Gregory Fine and Matthew T. Simpson to co-lead the Private Equity practice alongside current chair, Kurt Steinkrauss. The change is effective immediately.

As the pandemic and favorable market conditions drove record M&A and private equity dealmaking in 2021, Mintz’s Private Equity Practice handled a number of complex and impactful middle-market transactions for a growing number of private equity funds across the country spanning a variety of industries, including Charlesbank Capital Partners, DW Healthcare Partners, and Monomoy Capital Partners. In addition, the firm added several practitioners with extensive transactional knowledge to its deep bench to support private equity clients.